Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Disc Medicine Inc (IRON)

Disc Medicine Inc (IRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,309,545
  • Shares Outstanding, K 37,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -212,180 K
  • EBIT $ -236 M
  • EBITDA $ -244 M
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.08

Options Overview Details

View History
  • Implied Volatility 60.32% (-6.80%)
  • Historical Volatility 98.13%
  • IV Percentile 48%
  • IV Rank 21.47%
  • IV High 131.40% on 01/20/26
  • IV Low 40.89% on 09/12/25
  • Expected Move (DTE 11) 4.68 (7.28%)
  • Put/Call Vol Ratio 2.27
  • Today's Volume 36
  • Volume Avg (30-Day) 270
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 4,733
  • Open Int (30-Day) 5,675
  • Expected Range 59.56 to 68.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.55
  • Number of Estimates 7
  • High Estimate -1.48
  • Low Estimate -1.59
  • Prior Year -1.02
  • Growth Rate Est. (year over year) -51.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.00 +60.57%
on 02/13/26
76.14 -15.64%
on 02/10/26
-9.31 (-12.66%)
since 02/09/26
3-Month
40.00 +60.57%
on 02/13/26
94.50 -32.04%
on 12/12/25
-27.49 (-29.97%)
since 12/09/25
52-Week
30.82 +108.40%
on 04/09/25
99.50 -35.45%
on 12/08/25
+8.56 (+15.38%)
since 03/07/25

Most Recent Stories

More News
Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors

New York, New York--(Newsfile Corp. - March 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning...

IRON : 64.23 (+4.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...

IRON : 64.23 (+4.99%)
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 ...

IRON : 64.23 (+4.99%)
Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 64.23 (+4.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON).  Such investors are advised...

IRON : 64.23 (+4.99%)
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP

FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the...

IRON : 64.23 (+4.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...

IRON : 64.23 (+4.99%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...

IRON : 64.23 (+4.99%)
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

IRON : 64.23 (+4.99%)
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis...

IRON : 64.23 (+4.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.

See More

Key Turning Points

3rd Resistance Point 72.63
2nd Resistance Point 69.89
1st Resistance Point 67.06
Last Price 64.23
1st Support Level 61.49
2nd Support Level 58.75
3rd Support Level 55.92

See More

52-Week High 99.50
Fibonacci 61.8% 73.26
Fibonacci 50% 65.16
Last Price 64.23
Fibonacci 38.2% 57.06
52-Week Low 30.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar